Hyperglycemia following an acute stroke is associated with worse clinical outcomes: growth of infarction and conversion to a hemorrhagic stroke. To treat hyperglycemia subcutaneous insulin on a sliding scale is the standard of care. The SHINE clinical trial demonstrated that intensive glucose control of hyperglycemia following an acute stroke did not result in a significant difference in favorable functional outcomes at 90 days compared with hyperglycemia managed with standard glucose control. In addition, patients who managed with intensive glucose control experienced more frequent episodes of hypoglycemia.
Continuous intravenous insulin is the standard of care in critically ill patients with diabetic ketoacidosis or hyperosmolar hyperglycemia.
Learn more about type 2 diabetes.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori. Fast Five Quiz: Type 2 Diabetes and Cerebrovascular Disease - Medscape - Apr 27, 2022.